The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Open accessAbstract
Gut dysbiosis is commonly observed in patients with cirrhosis and chronic gastrointestinal disorders; however, its effect on antitumor immunity in the liver is largely unknown. Here we studied how the gut microbiome affects antitumor immunity in cholangiocarcinoma. Primary sclerosing cholangitis (PSC) or colitis, two known risk factors for cholangiocarcinoma which promote tumor development in mice, caused an accumulation of CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). A decrease in gut barrier function observed in mice with PSC and colitis allowed gut-derived bacteria and lipopolysaccharide to appear in the liver and induced CXCL1 expression in hepatocytes through a TLR4-dependent mechanism and an accumulation of CXCR2+ PMN-MDSCs. In contrast, neomycin treatment blocked CXCL1 expression and PMN-MDSC accumulation and inhibited tumor growth even in the absence of liver disease or colitis. Our study demonstrates that the gut microbiome controls hepatocytes to form an immunosuppressive environment by increasing PMN-MDSCs to promote liver cancer. Significance: MDSCs have been shown to be induced by tumors and suppress antitumor immunity. Here we show that the gut microbiome can control accumulation of MDSCs in the liver in the context of a benign liver disease or colitis. See related commentary by Chagani and Kwong, p. 1014. This article is highlighted in the In This Issue feature, p. 995
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Lozupone, C. A., Turnbaugh, P. J., Fierer, N., & Knight, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000080107 · Cited by 9,711
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“DiscUssiON The gut microbiome has profound effects on systemic immune responses, and it has been recognized as an important regulator of antitumor immunity (1, 3).”
BackgroundHoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., & Akira, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3749 · Cited by 3,374
Intestinal epithelial cells: regulators of barrier function and immune homeostasis
Peterson, L. W., & Artis, D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3608 · Cited by 3,173
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“DiscUssiON The gut microbiome has profound effects on systemic immune responses, and it has been recognized as an important regulator of antitumor immunity (1, 3).”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“As a matter of fact, both protumor and antitumor functions have been reported, and activation of TLR4 on dendritic cells has been found to improve antigen presentation and lead to better activation of cytotoxic T cells (70), whereas the opposite has been seen in DEN–CCl4-induced HCC (67).”
BackgroundCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“CXCL1 is the main ligand of CXCR2 in mice (34).”
BackgroundDextran Sulfate Sodium (DSS)‐Induced Colitis in Mice
Chassaing, B., Aitken, J. D., Malleshappa, M., & Vijay‐Kumar, M. (2014) · Current Protocols in Immunology · doi:10.1002/0471142735.im1525s104 · Cited by 2,090
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Dysbiosis of the gut microbiota in disease
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.26191 · Cited by 1,710
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Bullman, S., Pedamallu, C. S., Sicinska, E., Clancy, T. E., Zhang, X., Cai, D., Neuberg, D., Huang, K., Guevara, F., Nelson, T., et al. (2017) · Science · doi:10.1126/science.aal5240 · Cited by 1,574 · cited 1×
“The contribution of MDSCs to colitis-associated tumorigenesis is well established (53, 54), and gut-derived commensal bacteria have emerged as important factors during initiation and promotion of colon cancer (55, 56).”
BackgroundHospital-Acquired Infections Due to Gram-Negative Bacteria
Peleg, A. Y., & Hooper, D. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0904124 · Cited by 1,495
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,307
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia
Aujla, S. J., Chan, Y. R., Zheng, M., Fei, M., Askew, D. J., Pociask, D. A., Reinhart, T. A., McAllister, F., Edeal, J., Gaus, K., et al. (2008) · Nature Medicine · doi:10.1038/nm1710 · Cited by 1,171
Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.152 · Cited by 1,160
Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria
Dejea, C. M., Fathi, P., Craig, J. M., Boleij, A., Taddese, R., Geis, A. L., Wu, X., DeStefano Shields, C. E., Hechenbleikner, E. M., Huso, D. L., et al. (2018) · Science · doi:10.1126/science.aah3648 · Cited by 1,105 · cited 1×
“The contribution of MDSCs to colitis-associated tumorigenesis is well established (53, 54), and gut-derived commensal bacteria have emerged as important factors during initiation and promotion of colon cancer (55, 56).”
BackgroundAltered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 969
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
Self-citationTranslocation of a gut pathobiont drives autoimmunity in mice and humans
Manfredo Vieira, S., Hiltensperger, M., Kumar, V., Zegarra-Ruiz, D., Dehner, C., Khan, N., Costa, F. R. C., Tiniakou, E., Greiling, T., Ruff, W., et al. (2018) · Science · doi:10.1126/science.aar7201 · Cited by 839
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · cited 2×
“MDSCs have been reported to promote liver cancer through inhibiting natural killer (NK)– or T-cell function (21, 39).”
BackgroundSelf-citationGut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
Dysbiosis in inflammatory bowel disease
Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004) · Gut · doi:10.1136/gut.53.1.1 · Cited by 743
Analysis of gene expression data using BRB-ArrayTools.
Simon, R. M., Lam, A., Li, M., et al. (2007) · PubMed · Cited by 689
Neutrophil and B Cell Expansion in Mice That Lack the Murine IL-8 Receptor Homolog
Cacalano, G., Lee, J., Kikly, K., Ryan, A. M., Pitts-Meek, S., Hultgren, B., Wood, W. I., & Moore, M. W. (1994) · Science · doi:10.1126/science.8036519 · Cited by 664
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Self-citationThe gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Analysis of Gene Expression Data Using BRB-Array Tools
Simon, R., Lam, A., Li, M.-C., Ngan, M., Menenzes, S., & Zhao, Y. (2007) · Cancer Informatics · doi:10.1177/117693510700300022 · Cited by 626
Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609 · cited 2×
“Only hepatic PMN-MDSCs, but not M-MDSCs, increased in Gram-negative bacteria–colonized germ-free mice, which could be explained by the different receptors on the two subsets (19, 33).”
BackgroundSelf-citationClements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.007 · Cited by 550
Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study
Shaib, Y. H., El-Serag, H. B., Davila, J. A., Morgan, R., & McGlynn, K. A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.048 · Cited by 546
Cholangiocarcinomas can originate from hepatocytes in mice
Fan, B., Malato, Y., Calvisi, D. F., Naqvi, S., Razumilava, N., Ribback, S., Gores, G. J., Dombrowski, F., Evert, M., Chen, X., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63212 · Cited by 529 · cited 3×
“Plasmids encoding activated AKT and YAP or AKT and Notch1 were delivered by hydrodynamic injection, which resulted in formation of cholangiocarcinoma after 4 weeks (36, 37).”
BackgroundMethodWelzel, T. M., Graubard, B. I., El–Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., & McGlynn, K. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.020 · Cited by 514
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505
Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection
Alves-Filho, J. C., Sônego, F., Souto, F. O., Freitas, A., Verri, W. A., Auxiliadora-Martins, M., Basile-Filho, A., McKenzie, A. N., Xu, D., Cunha, F. Q., et al. (2010) · Nature Medicine · doi:10.1038/nm.2156 · Cited by 486
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477 · cited 2×
“Only hepatic PMN-MDSCs, but not M-MDSCs, increased in Gram-negative bacteria–colonized germ-free mice, which could be explained by the different receptors on the two subsets (19, 33).”
BackgroundThe role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., Forgues, M., Pomyen, Y., Bhudhisawasdi, V., Lertprasertsuke, N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.009 · Cited by 434
Self-citationHydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Bacterial translocation of enteric organisms in patients with cirrhosis
Cirera, I., Martin Bauer, T., Navasa, M., Vila, J., Grande, L., Taurá, P., Fuster, J., Garcı́a-Valdecasas, J. C., Lacy, A., Suárez, M. J., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00013-1 · Cited by 432
Nakamoto, N., Sasaki, N., Aoki, R., Miyamoto, K., Suda, W., Teratani, T., Suzuki, T., Koda, Y., Chu, P.-S., Taniki, N., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0333-1 · Cited by 425
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., Ferrante, M., Van Assche, G., Van der Merwe, S., Vermeire, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311004 · Cited by 413
Necroptosis microenvironment directs lineage commitment in liver cancer
Seehawer, M., Heinzmann, F., D’Artista, L., Harbig, J., Roux, P.-F., Hoenicke, L., Dang, H., Klotz, S., Robinson, L., Doré, G., et al. (2018) · Nature · doi:10.1038/s41586-018-0519-y · Cited by 406
Self-citationToll-Like Receptor Signaling in the Liver
Schwabe, R. F., Seki, E., & Brenner, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.038 · Cited by 401
Loeuillard, E., Yang, J., Buckarma, E., Wang, J., Liu, Y., Conboy, C., Pavelko, K. D., Li, Y., O’Brien, D., Wang, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137110 · Cited by 369
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases
Soares, J.-B., Pimentel-Nunes, P., Roncon-Albuquerque, R., & Leite-Moreira, A. (2010) · Hepatology International · doi:10.1007/s12072-010-9219-x · Cited by 367
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Self-citation[Primary sclerosing cholangitis].
Molina Jurado, M., Ferrer, J., & Gómez, N. (1984) · PubMed · Cited by 335
Toll-like receptors as targets in chronic liver diseases
Mencin, A., Kluwe, J., & Schwabe, R. F. (2009) · Gut · doi:10.1136/gut.2008.156307 · Cited by 329
Gäbele, E., Dostert, K., Hofmann, C., Wiest, R., Schölmerich, J., Hellerbrand, C., & Obermeier, F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.035 · Cited by 324
Tag, C. G., Sauer-Lehnen, S., Weiskirchen, S., Borkham-Kamphorst, E., Tolba, R. H., Tacke, F., & Weiskirchen, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52438 · Cited by 306
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 215
Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis
Lemoinne, S., Kemgang, A., Ben Belkacem, K., Straube, M., Jegou, S., Corpechot, C., Saint-Antoine IBD Network, Chazouillères, O., Housset, C., & Sokol, H. (2020) · Gut · doi:10.1136/gutjnl-2018-317791 · Cited by 215
Wang, T., Fan, C., Yao, A., Xu, X., Zheng, G., You, Y., Jiang, C., Zhao, X., Hou, Y., Hung, M.-C., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.018 · Cited by 200
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 185
Self-citationLiao, L., Schneider, K. M., Galvez, E. J. C., Frissen, M., Marschall, H.-U., Su, H., Hatting, M., Wahlström, A., Haybaeck, J., Puchas, P., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316670 · Cited by 172
Self-citationYu, S. J., Ma, C., Heinrich, B., Brown, Z. J., Sandhu, M., Zhang, Q., Fu, Q., Agdashian, D., Rosato, U., Korangy, F., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.040 · Cited by 170
Self-citationCharacterization of animal models for primary sclerosing cholangitis (PSC)
Fickert, P., Pollheimer, M. J., Beuers, U., Lackner, C., Hirschfield, G., Housset, C., Keitel, V., Schramm, C., Marschall, H.-U., Karlsen, T. H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.006 · Cited by 167
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
Zhang, S., Song, X., Cao, D., Xu, Z., Fan, B., Che, L., Hu, J., Chen, B., Dong, M., Pilo, M. G., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.006 · Cited by 152
Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma
Høgdall, D., Lewińska, M., & Andersen, J. B. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.01.007 · Cited by 138
Tedesco, D., Thapa, M., Chin, C. Y., Ge, Y., Gong, M., Li, J., Gumber, S., Speck, P., Elrod, E. J., Burd, E. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.019 · Cited by 137
Gut microbiome in primary sclerosing cholangitis: A review
Little, R., Wine, E., Kamath, B. M., Griffiths, A. M., & Ricciuto, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2768 · Cited by 127
Ibrahim, M. L., Klement, J. D., Lu, C., Redd, P. S., Xiao, W. L., Yang, D., Browning, D. D., Savage, N. M., Buckhaults, P., Morse, H. C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.050 · Cited by 125
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Wang, G., Wang, Q., Liang, N. N., Xue, H., Yang, T., Chen, X., Qiu, Z., Zeng, C., Sun, T., Yuan, W., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2509-x · Cited by 111
Animal models of cholangiocarcinoma
Loeuillard, E. J., Fischbach, S. R., Gores, G. J., & Ilyas, S. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.026 · Cited by 86
Zannetti, C., Roblot, G., Charrier, E., Ainouze, M., Tout, I., Briat, F., Isorce, N., Faure‐Dupuy, S., Michelet, M., Marotel, M., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502301 · Cited by 81
Isolation of Non-parenchymal Cells from the Mouse Liver
Mohar, I., Brempelis, K. J., Murray, S. A., Ebrahimkhani, M. R., & Crispe, I. N. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2815-6_1 · Cited by 66
Isolation and Flow Cytometric Characterization of Murine Small Intestinal Lymphocytes
Couter, C. J., & Surana, N. K. (2016) · Journal of Visualized Experiments · doi:10.3791/54114 · Cited by 62
Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice
Cabrera-Rubio, R., Patterson, A. M., Cotter, P. D., & Beraza, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-48784-z · Cited by 61
Govaere, O., Cockell, S., Van Haele, M., Wouters, J., Van Delm, W., Van den Eynde, K., Bianchi, A., van Eijsden, R., Van Steenbergen, W., Monbaliu, D., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5228 · Cited by 61
Bigorgne, A., John, B., Ebrahimkhani, M. R., Shimizu‐Albergine, M., Campbell, J. S., & Crispe, I. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151063 · Cited by 47
Cholangiocarcinoma in patients with primary sclerosing cholangitis
Fung, B. M., & Tabibian, J. H. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000616 · Cited by 39
Donghi, D., Pechlaner, M., Finazzo, C., Knobloch, B., & Sigel, R. K. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1179 · Cited by 33
Models for Immuno-oncology Research
(2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.010 · Cited by 12
Carini, R., Cesaris, M. D., Splendore, R., & Albano, E. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)80974-0 · Cited by 10
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Metadata
- Authors
- Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., Wabitsch, S., Thovarai, V., Fu, J., Feng, D., Ruf, B., Cui, L. L., Subramanyam, V., Frank, K. M., Wang, S., Kleiner, D. E., Ritz, T., Rupp, C., Gao, B., Longerich, T., Kroemer, A., Wang, X. W., Ruchirawat, M., Korangy, F., Schnabl, B., Trinchieri, G., & Greten, T. F.
- Venue
- Cancer Discovery
- Published
- 2020-12-15
- Volume
- 11
- Issue
- 5
- Pages
- 1248-1267
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3112001494
- Cited by
- 257
- References
- 88
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.